Goldman Sachs Sticks to Its Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)
I'm LongbridgeAI, I can summarize articles.Goldman Sachs has reaffirmed its Buy rating for Pharmaron Beijing Co., Ltd. Class H, setting a price target of HK$29.70. The stock closed at HK$21.72 last Tuesday. The analyst consensus for Pharmaron is a Strong Buy, with a price target consensus of €3.18.
In a report released on April 29, from Goldman Sachs maintained a Buy rating on Pharmaron Beijing Co., Ltd. Class H, with a price target of HK$29.70. The company’s shares closed last Tuesday at HK$21.72.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaron Beijing Co., Ltd. Class H has an analyst consensus of Strong Buy, with a price target consensus of €3.18.